Background {#Sec1}
==========

Leg length discrepancy and short stature have multifactorial etiologies that may include congenital, developmental, infectious, or posttraumatic. Limb lengthening is an acceptable option to manage patients with these conditions \[[@CR1]--[@CR5]\]. First described by Alessandro Codivilla in the early 20th century \[[@CR6]\], this procedure gained popularity following the work of Gavriil Ilizarov and his development of the external fixation device \[[@CR7]\]. Advances in the field since then have led to a wider array of methods with which to lengthen bone. Currently, limb lengthening can be achieved by a variety of circular and unilateral external fixation devices, lengthening over nails (LON), and most recently lengthening with intramedullary telescoping rods \[[@CR8]--[@CR11]\]. Each technique carries with it the potential for significant complications \[[@CR12]--[@CR14]\]; many risk factors have been identified \[[@CR15]\].

All methods of limb lengthening rely on the process of distraction osteogenesis (DO), whereby an osteotomy is performed and the bone ends are gradually displaced apart to facilitate the growth of regenerate bone \[[@CR16]--[@CR19]\]. Several factors may influence the rate at which bone regenerates; distraction rate and bone quality may be the most important \[[@CR19]--[@CR23]\]. Although a successful procedure, problems associated with the growth of the regenerate bone have been commonly described. These difficulties may include premature consolidation, but also slow regenerate bone formation, delayed mineralization, or nonunion, which may contribute to the high rates of patient morbidity seen in limb lengthening procedures \[[@CR24]\]. Many options, both pharmacological and non-pharmacological, have been explored to enhance the rate of growth of regenerate bone in humans and animals \[[@CR25]--[@CR29]\]. Within the non-pharmacological alternatives, studies have described the use of low intensity pulsed ultrasound (LIPUS) as well as pulsed electromagnetic fields (PEMF) during DO to enhance bone regeneration in animals \[[@CR30]--[@CR35]\]. Studies have demonstrated that LIPUS and PEMF stimulate many different cell types involved in bone healing, including osteoblasts, osteoclasts, chondrocytes, and mesenchymal cells \[[@CR36]\]. In addition, these methods of stimulation have also been shown to increase the expression of numerous genes (including IGF and TGF-β), the size of the chondrocyte population, the synthesis of extracellular matrix, and the rate of osteoblast differentiation \[[@CR37]--[@CR39]\].

While previous studies have attempted to assess the efficacy of these alternatives in humans \[[@CR40]--[@CR46]\], there has not been a study that has systematically evaluated the success of LIPUS and PEMF in stimulating the regenerate bone growth and improving patient outcomes. Therefore, the purposes of this study were: (1) to determine the efficacy of these two non-pharmacological alternatives utilized to stimulate regenerate bone healing and (2) to establish the success rate of these alternatives in decreasing treatment time and reducing the complications during limb lengthening.

Methods {#Sec2}
=======

We performed a systematic literature search to determine the possible alternatives to stimulate regenerate bone healing. This was performed utilizing the preferred reporting items for systematic review and meta-analysis protocols (PRISMA) guidelines \[[@CR47]\]. The electronic databases Medline, Embase and Ovid were queried to find all relevant studies published in literature until July 2015. We utilized the search strings "limb lengthening," "distraction osteogenesis," "bone transport," or "regenerate bone," which yielded a total of 16372 results. Excluding non-human studies returned 10384 publications. Further limiting the search string to studies written only in English returned 9044 studies.

The titles and abstracts of these studies were then carefully reviewed utilizing specific inclusion and exclusion criteria. We specifically included studies evaluating the use of LIPUS or PEMF to stimulate the regenerate bone formation in limb lengthening patients. Single case reports, review studies, and literature involving maxillary or mandibular DO and craniofacial or maxillofacial surgery were excluded. After applying these inclusion and exclusion criteria, 7 studies were determined to be relevant. The citations for these studies were cross-referenced; however, no additional relevant studies were found (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Flowchart of search methodology and inclusion/exclusion criteria

The entire process was performed by one of the authors (JJJ) and then fully repeated by another (AVV), blinded from the previously performed search to ensure all pertinent studies were included. We searched for specific endpoints within each study, which included age, bone (humerus, tibia, or femur) lengthened, average distraction distance, healing index, bone mineral density, and indication for bone lengthening. The information obtained from the literature review was logged into an electronic spreadsheet (Microsoft Excel, Microsoft Office, Redmond, Washington). Then, utilizing a Random Model Effects, Forest-Plots were obtained to compare the differences in bone healing index with and without the use of a bone stimulator. This was performed with the aid of statistical software (MedCalc, MedCalc Software version 15.2, Ostend, Belgium). This study was performed without external funding.

Results {#Sec3}
=======

The seven studies included in our final analysis evaluated a total of 192 cases of limb lengthening and averaged 27 limbs lengthened per study \[[@CR40]--[@CR46]\]. One hundred fifty-three patients comprised of 118 males and 35 females with a mean weighted age of 26 years (range of means 8 to 39 years) underwent limb lengthening procedures. Thirty-nine of these patients underwent bilateral, symmetrical lengthening with 30 patients receiving PEMF on one of the lengthened limbs, 7 receiving LIPUS bilaterally, and 2 patients in the control group. Across all studies included in the analysis, 155 tibiae, 25 femora, and 12 humeri had undergone the index procedure (Table [1](#Tab1){ref-type="table"}).Table 1Study demographicsAuthors, YearNumber of PatientsNumber of LimbsMean Age in Years (Range)Tibia (%)Femur (%)Humerus (%)Modality UsedSalem and Schmelz, 2014 \[[@CR43]\]212131 (− to -)100 %0 %0 %LIPUSEl-Mowafi and Mohsen, 2005 \[[@CR41]\]202035 (18 to 45)100 %0 %0 %LIPUSDudda et al., 2011 \[[@CR40]\]363639 (16 to 69)100 %0 %0 %LIPUSGebauer and Correll, 2005 \[[@CR42]\]13177.85 (− to -)94 %6 %0 %LIPUSGonzalez et al., 2005 \[[@CR44]\]306011 (− to -)47 %33 %20 %PEMFEyres et al., 1996 \[[@CR45]\]131817.9 (11 to 19)78 %22 %0 %PEMFGold and Wasserman, 2005 \[[@CR46]\]202034 (18 to 50)100 %0 %0 %LIPUS

A total of 103 limbs were stimulated; of these, 63 were stimulated with LIPUS and 40 with PEMF. The mean amount of limbs stimulated per study was 15. Most studies applied LIPUS or PEMF concurrently during the distraction phase, with the exceptions of the studies by El-Mowafi and Mohsen \[[@CR41]\] (LIPUS initiated one day after cessation of distraction) and Gebauer and Correll \[[@CR42]\] (LIPUS initiated if the calcification of the newly formed bone did not improve for at least 3 months). The mean distraction distance in the treatment cohort was 8.1 cm (range of means 6.1 to 11.3 cm). For those studies reporting, the mean healing index for the treatment cohort was 33.7 days/cm ranging from 30 to 39 days/cm (Table [2](#Tab2){ref-type="table"}). A total of 89 limbs with an average of 15 limbs per study underwent lengthening but were not stimulated. The mean distraction distance in the control cohorts was 8.2 cm (range of means 6.1 to 11.3 cm). A mean healing index of 45.4 days/cm ranging from 44 to 48 days/cm was found in those studies that reported the parameter (Table [2](#Tab2){ref-type="table"}).Table 2Specific Outcome MeasuresAuthors, YearCohortNumber of LimbsMean Distraction in cm (Range)Mean Healing Index in days/cm (± SD)Mean Time to Fixator Removal (days) (±SD)Mean Time to Corticalisation (days) (±SD)Salem and Schmelz, 2014 \[[@CR43]\]Stimulated127.9 (− to -)33 (± −)NRNRControl97.9 (− to -)45 (± −)NRNREl-Mowafi and Mohsen, 2005 \[[@CR41]\]Stimulated106.1 (5 to 8)30 (±2.96)NRNRControl106.1 (5 to 8)48 (±9.76)NRNRDudda et al., 2011 \[[@CR40]\]Stimulated166.6 (2.5 to 14.0)32.8 (±13.1)NRNRControl206.6 (2.5 to 14.0)44.4 (±6.8)NRNRGebauer and Correll, 2005 \[[@CR42]\]Stimulated177.06 (2.5 to 14.0)*N =* 7, calcification after 6 weeks; *N =* 10, bridging observed after 12 weeks.Gonzalez et al., 2005 \[[@CR44]\]Stimulated3011.3 (5.3 - 15.3)NR308.3 (±62.82)279.6 (±68.4)Control3011.3 (53 to 153)NR339.5 (±61.17)313.5 (±60.6)Eyres et al., 1996 \[[@CR45]\]Stimulated107.6 (− to -)39 (±4)NRNRControl87.6 (− to -)44 (±6)NRNRGold and Wasserman, 2005 \[[@CR46]\]Stimulated810.25 (8 to 14)NR417.3 (± −)NRControl129.46 (4 to 20)NR501.3 (± −)NR*NR* Not Reported

Of the 141 patients described in these studies, 70 were treated with a circular external fixation device, 64 were treated with a monolateral external fixator, and 7 were treated with hybrid fixation (unilateral and circular ring fixators) \[[@CR48]\]. In terms of the indication for the procedure, there were 40 posttraumatic leg length discrepancies (LLD), 14 congenital LLD, 38 symmetric growth restrictions (i.e. achondroplasia), and 5 had unclassified indications (Table [3](#Tab3){ref-type="table"}). Additionally, eight bone transports were included in our study. Only two studies described specific complications: El-Mowafi and Mohsen \[[@CR41]\] reported 5 complications, which were 1 case of delayed union in the treatment group, 4 cases of delayed union in the control group, and 1 failure to consolidate in the control group. Dudda et al. \[[@CR40]\] reported 6 complications, which were 1 amputation in both the treatment and control groups, 1 pseudoarthrosis in the treatment group, and 3 pseudoarthroses in the control group (Table [3](#Tab3){ref-type="table"}). All of the other studies evaluated failed to mention complication rates.Table 3Type of fixator, indications for lengthening, and complicationsIndications for Lengthening (number)Authors, YearFixator typeBone TransportPost-traumatic LLDCongenital LLDSymmetric Growth RestrictionsOther LLDComplicationsSalem and Schmelz, 2014 \[[@CR43]\]Circular021000NREl-Mowafi and Mohsen, 2005 \[[@CR41]\]Circular018Congenital Anterolateral Bowing of Tibia (2)004 delayed unions, 1 failure to consolidateDudda et al., 2011 \[[@CR40]\]Monolateral (23), Circular (6), hybrid (7)0NRNRNRNR2 amputations (infection), 4 PseudoarthrosesGebauer and Correll, 2005 \[[@CR42]\]Circular01Fibular hemimelia (5), CFD (1), Congenital Pseudoarthrosis (1)Achondroplasia (3), Russell-Silver syndrome (1)Polio (1)NRGonzalez et al., 2005 \[[@CR44]\]Monolateral00Chondrodysplasia (1), fibular hemimelia (1)Achondroplasia (24), Turner\'s Syndrome (4)0NREyres et al., 1996 \[[@CR45]\]Monolateral (16), Circular (2)00Congenital short femur and tibia (2), Fibular hemimelia (1)Achondroplasia (4), Turner\'s Syndrome (2)Polio (1), infection (1), radiation (1), Ollier\'s (1)NRGold and Wasserman, 2005 \[[@CR46]\]Circular80000NR*NR* Not Reported

Of the seven studies, only four studies provided detailed information regarding the differences in the healing index between the stimulated (treatment) and non-stimulated (control) cohorts. We found that the mean healing index was 11.7 days/cm faster when using bone stimulation that in the comparison cohorts (33.7 vs 45.4 days/cm), with a standardized mean difference of 1.16 (95 % Confidence Intervals of 0.40 to 1.91; *p =* 0.003), favoring a better healing index within the stimulation cohort when compared to the control cohorts (Fig. [2](#Fig2){ref-type="fig"}). Of the studies that did not provide sufficient data to incorporate into the analysis, Gonzalez et al. \[[@CR44]\] reported a shorter time to fixator removal (308.3 vs. 339.5 days), shorter time to corticalization (279.6 vs. 313.5 days), increased callus thickness (31.2 vs. 21.8 mm), increased cortical thickness (2.73 vs. 2.63 mm), and increased bone callus density (85.7 vs. 69.8 g/cm^3^) in limbs stimulated with PEMF compared to those that were not. Similarly, Gold and Wasserman \[[@CR46]\] found a decreased time in external fixation frame (13.91 vs. 16.71 months) and a decreased external fixation index (time in frame per cm bone transported of 1.34 vs. 2.02; Table [2](#Tab2){ref-type="table"}). Gebauer and Correll \[[@CR42]\] did not utilize a control group but demonstrated that LIPUS can successfully salvage delayed unions or non-unions following limb lengthening (DO).Fig. 2Forest-plot demonstrating the healing index between both cohorts. Forest-plot showing the effects of LIPUS or PEMF treatment on mean healing index. Each square represents the size of the study while bars represent confidence intervals. The diamond at the bottom of the graph shows the average effect size with a random effect model of the four studies; the lateral tips of the diamond represent the associated confidence interval. Note that a standardized mean difference lower than zero (0), favors stimulation (less time for bone healing)

Discussion {#Sec4}
==========

Although limb lengthening has been successfully utilized to treat leg length discrepancies or short stature, the procedure is not without its inherent risks and complications \[[@CR15]\]. Of these, many are related to slower bone healing or even non-unions. There has been a recent increase in the popularity of LIPUS in the fracture/non-union setting, and a recent meta--analysis by Rutten et al. \[[@CR49]\] described that LIPUS was able to reduce the time to radiographic fracture healing. Similarly, in the setting of limb lengthening we found that both LIPUS and PEMF improved the healing index and decreased the amount of time needed to consolidate regenerate bone and remain in fixation. Time in fixation has been suggested to be a predictor of complications in these procedures \[[@CR15]\]; thus, the use of LIPUS or PEMF may reduce the incidence of associated complications. It is important to note that while LIPUS and PEMF have now been demonstrated to be efficacious in both fracture healing and DO, these two processes of bone healing differ in several key ways. While fracture healing and DO both employ intramembranous and endochondral bone formation, in fracture healing endochondral bone formation is the primary method of ossification, while in DO, intramembranous ossification predominates \[[@CR50], [@CR51]\]. In comparable times post-injury, DO exhibits large amounts of unmineralized osteoid in the central region of the distraction gap, while fracture callus has already calcified. During fracture healing the process of angiogenesis is initiated between days 7 and 14 while in DO, angiogenesis only occurs only after active distraction commences. There are also molecular differences between the two processes: in fracture healing, IL-1, IL-6, and TNF-α are elevated soon after injury, compared to DO in which only IL-1 and IL-6 become significantly elevated \[[@CR52]\].

There were several limitations in this study. Due to the low frequency of limb lengthening procedures, and the even rarer number of studies that have evaluated the stimulation of the regenerate bone, the overall size of the analyzed cohort is small. In addition, the studies that were included in our analysis exhibited heterogeneity in terms of mean patient age, indication for lengthening (congenital condition vs. trauma), type of bone lengthened, method of lengthening, as well as the reported outcome parameters. Hence, the overall reproducibility of our results may be limited. However, this is the first study that has comprehensively evaluated both LIPUS and PEMF to stimulate bone formation following limb lengthening. In addition, although we found a significantly faster healing time, this may not necessarily apply to the clinical and patient reported outcome measures, which require further study. Also, certain studies included in the analysis were unblinded trials, which may have introduced bias into the results, however, these studies did not receive funding from either party. While there was insufficient data to generate a funnel plot, sources of funding and competing interests for each individual study were carefully reviewed to assess for possible bias. Only one study reported a possible conflict of interest as the senior author is a consultant for the Exogen manufacturer; however, the authors received nothing of value \[[@CR42]\].

The adjuvant properties of LIPUS and PEMF for bone healing have been known for several years. One of the first studies that evaluated regenerate bone stimulation in animals was described by Pilla et al. \[[@CR53]\], who assessed the regenerative properties of LIPUS in fractured rabbit fibulae (*n =* 139 rabbits). They found that LIPUS-stimulated fibulae exhibited a biomechanical healing rate 1.7 times faster than that of unstimulated fibulae. Fredericks et al. \[[@CR35]\] found that following DO, PEMF-stimulated rabbit tibiae exhibited higher mean torque-to-fracture values compared with unstimulated tibiae. Several other studies have evaluated the potentially beneficial effects of LIPUS and PEMF on fracture healing \[[@CR54]--[@CR59]\]. Heckman et al. \[[@CR55]\] demonstrated a statistically significant decrease in the healing time of fractured tibiae treated with LIPUS as compared to untreated tibiae, while Sharrard \[[@CR57]\] showed that PEMF stimulation of delayed unions contributed to better outcomes in stimulated tibiae compared with unstimulated tibiae.

There are also invasive alternatives that could be used to stimulate the regenerate bone, either in place of or in conjunction with the previously mentioned modalities. A study by Lee et al. \[[@CR27]\] demonstrated that bone marrow aspirate combined with platelet rich plasma (PRP) injection following DO led to a significant improvement in the mean cortical healing indices as compared to an untreated cohort (*p \<* 0.001). Similarly, Kitoh \[[@CR25]\] showed that transplanted bone marrow cells along with PRP improved average healing indices of patients treated for short stature or LLD as compared to an untreated cohort (*p =* 0.0019 and *p =* 0.0031, respectively). These modalities have also been studied in several animal studies with successful outcomes; however, more prospective, randomized controlled trials are needed to clarify their effects \[[@CR26], [@CR28]--[@CR30]\].

Conclusion {#Sec5}
==========

Though limited by the inadequate number of studies and small number of patients in these studies, the results we obtained and the literature we reviewed support the use of LIPUS or PEMF following DO. The use of either modality improves regenerate bone formation and decreases the healing time and the amount of time spent in fixation. This may prevent complications such as delayed union, nonunion, or malunion, as well as decrease the morbidity associated with prolonged external fixation. At the current time however, the use of ultrasound is largely limited to nonunion cases. The vast majority of insurances will not reimburse for this modality unless the patient is 3 months postoperative and the affected limb remains non-united. Despite these restrictions, we believe that surgeons performing limb lengthening should consider the possibility of utilizing these non-invasive methods for regenerate bone stimulation. However, future studies with larger cohorts are needed to fully evaluate the potential success of these modalities.
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